The FDA on September 22, 2015 approved LONSURF® for the treatment of patients with metastatic colorectal cancer, who have been previously treated with Fluoropyrimidine, Oxaliplatin and Irinotecan-based chemotherapy, an anti-VEGF biologic product, and an anti-EGFR monoclonal antibody, if RAS wild-type. LONSURF® is a product of Taiho Oncology, Inc.
Bottom Ad
Advertisement
Subscribe
